StreetInsider.com News Articles

Alkermes (ALKS) PT Raised to $54 at Needham

Thu, 18 Jun 2026 07:06:13 -0400

(Updated - June 18, 2026 7:06 AM EDT)

Needham analyst Ami Fadia raised the price target on Alkermes (NASDAQ: ALKS) to $54.00 (from $50.00) while maintaining a Buy rating.

The analyst commented: "ALKS presented updated data from the VIBRANCE-2 study at the SLEEP conference (LINK) where the efficacy profile for alixorexton continued to demonstrate improvement through week 13 (OLE) on ESS. We also saw improvement in exploratory endpoints of PROMIS-fatigue and BC-CCI supporting development in indications such as fatigue in MS and Parkinson's Disease. 18 mg emerged as the dose with the best overall profile, with no discontinuations, and AE rates for

Alkermes (ALKS) PT Raised to $54 at Needham

Thu, 18 Jun 2026 07:06:13 -0400

(Updated - June 18, 2026 7:06 AM EDT)

Needham analyst Ami Fadia raised the price target on Alkermes (NASDAQ: ALKS) to $54.00 (from $50.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)

Thu, 18 Jun 2026 06:43:09 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $43.00 price target on Alkermes (NASDAQ: ALKS).

The analyst commented: "Detailed results from the Vibrance-2 study, presented at Sleep 2026, provided additional insights into the broader effects of alixorexton on NT2 patients. In addition to the previously reported improvements in the MWT and ESS, new exploratory endpoints demonstrated enhancements in fatigue and cognitive function at higher doses, as assessed by the PROMIS-Fatigue and BC-CCI. At week 8, alixorexton demonstrated placebo-adjusted improvements in PROMIS-Fatigue scores of -5.3 and -8.8 points in the 14mg and 18 mg cohorts, respectively. In the BC-CCI, the

Alkermes narcolepsy drug meets phase 2 trial endpoints

Wed, 17 Jun 2026 16:15:23 -0400

Alkermes plc (NASDAQ: ALKS) presented detailed results from its Vibrance-2 phase 2 study of alixorexton in adults with narcolepsy type 2 (NT2) at the 40th annual meeting of the Associated Professional Sleep Societies in Baltimore.

The study, which enrolled 93 participants, met its dual primary endpoints. Alixorexton demonstrated statistically significant improvements from baseline compared to placebo on the Maintenance of Wakefulness Test (MWT) at the 14 mg (p=0.049) and 18 mg (p=0.047) doses, and on the Epworth Sleepiness Scale (ESS) at the 18 mg dose (p=0.046) at week eight.

Participants had a mean sleep latency of approximately six minutes at baseline. At

Alkermes narcolepsy drug meets phase 2 trial endpoints

Wed, 17 Jun 2026 16:15:23 -0400

Participants had a mean sleep latency of approximately six minutes at baseline. At

Alkermes narcolepsy drug meets phase 2 trial endpoints

Wed, 17 Jun 2026 16:15:23 -0400

Participants had a mean sleep latency of approximately six minutes at baseline. At

Alkermes narcolepsy drug meets phase 2 trial endpoints

Wed, 17 Jun 2026 16:15:23 -0400

Participants had a mean sleep latency of approximately six minutes at baseline. At

Alkermes narcolepsy drug meets phase 2 trial endpoints

Wed, 17 Jun 2026 16:15:23 -0400

Participants had a mean sleep latency of approximately six minutes at baseline. At

Alkermes narcolepsy drug meets phase 2 trial endpoints

Wed, 17 Jun 2026 16:15:23 -0400

Participants had a mean sleep latency of approximately six minutes at baseline. At

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026